Kymera Therapeutics Inc. KYMR
$86.66
▲ +3.91% 24H
About
Kymera Therapeutics Inc. is a pioneering biotechnology company focused on the development of targeted protein degradation therapies. These therapies are aimed at disease-causing proteins that have traditionally been considered "undruggable." Kymera's primary function is to leverage its proprietary drug discovery platfo…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees253
TickerKYMR
Statistics
Market Cap$7.12B
Revenue (TTM)$39.2M
Net Income-$311.4M
Net Margin-794.0%
EPS$-3.69
P/E-22.48
P/S132.57
P/B4.43
EV/EBITDA-16.82
ROE-27.1%
Dividend Yield—
Price$86.66
Data: Twelve Data · Revenue = mcap / P/S